About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

RECRUITINGNCT05756244

PRospective Evaluation of Peripartum Anticoagulation ManaGement for ThrOmboembolism

The PREP and GO study is an international multicentre prospective cohort evaluating anticoagulation management strategies around labor and delivery and the postpartum period.

Lead sponsor: University of Calgary•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Jill Baxter, BSc

CONTACT

403-220-7103 [email protected]

Leslie Skeith, MD

CONTACT

403-944-5246 [email protected]

Sponsors

Lead Sponsor

University of Calgary

The goal of this study is to provide quality data using standardized outcome definitions on postpartum bleeding events, venous thromboembolism (VTE) risk, delivery experience outcomes and health care utilization for intrapartum and postpartum anticoagulation management among pregnant individuals on low-molecular-weight heparin (LMWH) for prevention of treatment of VTE.

Age

18 - 60 years

Sex

FEMALE

Healthy Volunteers

No

Inclusion Criteria

•18 years of age or older
•Requires anticoagulation during the antepartum period of pregnancy for a VTE indication, including at least one of:
•1. Objectively confirmed VTE (DVT, superficial vein thrombosis \[SVT\], PE or unusual site thrombosis) diagnosed during the current pregnancy;
•2. Objectively confirmed VTE diagnosed in a prior pregnancy;
•3. Objectively confirmed VTE diagnosed when not pregnant;
•4. Inherited or acquired thrombophilia requiring anticoagulation.
•Receiving any dose or type of LMWH during the antepartum period

Exclusion Criteria

•Anticoagulation for a non-VTE indication, including prosthetic heart valves, atrial fibrillation, prevention of placenta-mediated pregnancy complications, or prevention of recurrent pregnancy loss (participants can be included with a diagnosis of antiphospholipid syndrome (APS) with or without thrombotic events)
•Unable to provide or declined consent.
•Home or birthing centre planned delivery.

Related studies

Aspiration Thrombectomy Using the Symphony or Prodigy System

NCT07350499 · Arterial Thromboembolism, Venous Thromboembolism, and more

RECRUITINGPhase 3

REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants

NCT07213778 · Symptomatic Venous Thromboembolism (VTE)

RECRUITINGPhase 4

Statins to Prevent Cancer Associated Blood Clots

NCT07303816 · Venous Thromboembolism, Cancer, and more

Odevixibat Pregnancy and Lactation Surveillance Program: A Study to Evaluate the Safety of Odevixibat During Pregnancy and/or Lactation

NCT06258902 · Pregnancy Related

Clinical Antenatal Randomised Study to CharactErise Key Roles of TetrahydroFOLate in HyperTensive Pregnancies

NCT05434195 · Pre-Eclampsia, Pregnancy Induced Hypertension, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: November 28, 2025Terms

Trial snapshot

StatusRECRUITING

Phase—

Enrollment825

Start dateApr 2023

Last updatedNov 28, 2025

Condition

Pregnancy Related Venous Thromboembolism

Locations shown

Duke University Hospital

Durham, North Carolina

Foothills Medical Centre

Calgary, Alberta

Royal Alexandra Hospital

Edmonton, Alberta

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 28, 2025Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions